Physician profile
Khalid Iqbal
NPI 1598755993
$2,046.46
in general payments reported to CMS, 2019-2025
18 companies · $626 in 2025
The $626 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2021: $17.80 · 2022: $427 · 2023: $523 · 2024: $345 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.19 |
| Education | $150.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $297.79 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $262.09 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $236.65 | 2022-2025 | Acthar |
| Amgen INC. | $179.03 | 2019-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $155.84 | 2022-2023 | Lupkynis |
| Vantive US Healthcare LLC | $146.07 | 2025 | Renal - Pd |
| Calliditas Therapeutics US INC. | $119.13 | 2022-2025 | Tarpeyo |
| Baxter Healthcare | $111.21 | 2023-2024 | Renal - Chronic, Renal - Pd |
| Fresenius USA Marketing, INC. | $101.30 | 2025 | Velphoro |
| Akebia Therapeutics INC | $98.01 | 2019-2024 | Vafseo |
| Ardelyx, INC. | $85.25 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $77.05 | 2019-2024 | Farxiga |
| Travere Therapeutics, INC. | $66.13 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $26.53 | 2025 | |
| Daiichi Sankyo INC. | $25.23 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.93 | 2022 | |
| Apellis Pharmaceuticals, INC. | $20.69 | 2025 | Empaveli |
| Idorsia Pharmaceuticals US INC | $16.53 | 2025 | Tryvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.